EligibleTrials
Conditions › High cholesterol › NCT06451770

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Recruiting · NCT06451770 · Interventional (participants receive a specific treatment) · Lead sponsor: Verve Therapeutics, Inc.

View the official record on ClinicalTrials.gov →
High cholesterol

Interventions studied

VERVE-201

What this trial is about

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.

Who can take part

Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

16 locations listed across 2 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.